Navigation Links
Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
Date:8/25/2013

l carcinoma. Nexavar is thought to inhibit both the tumor cell and tumor vasculature. In in vitro studies, Nexavar has been shown to inhibit multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in more than 100 countries. Nexavar is also being evaluated by Bayer and Onyx, international study groups, government agencies and individual investigators in a range of cancers.

Important Safety Considerations For Nexavar® (sorafenib) Tablets
Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction.

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar.

Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, if required.

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Nexavar should be discontinued if Stevens-Johnson Syndrome or toxic epidermal necrolysis are suspected as these may be life threatening.

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar. Discontinue Nexavar in the event of a gastrointestinal perforation.

<
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
(Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
(Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
(Date:6/30/2015)... ... June 30, 2015 , ... ... ready-to-drink sponsor of two leading organizations dedicated to raising worldwide awareness of the ... I AM ADAPTIVE™ is now the official charity of FitAID. I AM ADAPTIVE ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... market research, has launched a new reimbursement insurance policy tracking and analysis service. ... receive US insurance policy and rate updates in real-time from hundreds of insurance ...
(Date:6/30/2015)... Louis, MO (PRWEB) , ... June 30, 2015 ... ... attorneys handling national testosterone claims alleging heart attack and stroke incidents are linked ... after Independence Day. The Case Management Conference is scheduled for July 9, 2015, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... India ... subsidiary of Aetna, Inc. for its visitor health insurance plans that provides coverage for ... network of providers nationwide to enable visitors to obtain services from most experienced health ...
(Date:6/30/2015)... ... 2015 , ... Under Armour’s new baselayer for football players—Gameday ... other padding in football. , Developed in partnership with D3O®, a leading UK-based ... engineered with D3O protective polymer. This radical polymer material has a unique molecular ...
Breaking Medicine News(10 mins):Health News:LifeAID Beverage Company Partners With The Adaptive Movement 2Health News:LifeAID Beverage Company Partners With The Adaptive Movement 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 2Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 3Health News:Testosterone Lawsuit News: July Conference on Bellweather Trials 4Health News:India Network Announces Accessibility of First Health PPO Nationwide Network for Visitor Health Insurance Plan Participants Effective July 1, 2015 2Health News:India Network Announces Accessibility of First Health PPO Nationwide Network for Visitor Health Insurance Plan Participants Effective July 1, 2015 3Health News:Under Armour Launches Advanced Gameday Armour® Max Protection System For The Gridiron 2
... Executive Director, Campaign for Tobacco-Free ... ... from William V. Corr, Executive Director, Campaign for,Tobacco-Free Kids: Last night, ... majority voting for a 61-cent-per-pack increase in the,federal cigarette tax to help ...
... in diagnosing the condition, study says , , FRIDAY, Sept. 28 ... before, during or after pregnancy, a new study finds. , ... her baby and her entire family, according to the report ... of Psychiatry . , "The prevalence of women diagnosed with ...
... Stroke ... Management Market, ... "Simcere"), the manufacturer of the innovative,anti-cancer medication Endu and a ... announced that it has,entered into a definitive agreement to acquire ...
... Sept. 28 ABR-Affinity,BioReagents, a leading global ... 100% Quality Guarantee. Launched in 2003, ... bolster confidence in research antibodies. Antibodies are,considered ... of early-stage life science,research and drug discovery. ...
... Patients with acute lung injury (ALI) are nearly one-third less ... require board-certified critical care physicians to oversee patient care, as ... physician to oversee admission and case management. , ALI ... patients with pneumonia or sepsis. Mortality rates are high -- ...
... centuries, meditation has recently inspired research into its ... heart attack prevention. A painful, progressive autoimmune ... high risk of depressiondouble the risk of the ... psychological distress. Increasingly, RA patients are turning ...
Cached Medicine News:Health News:President Bush Should Protect Kids, Not Big Tobacco By Signing Bill to Increase Cigarette Tax, Fund SCHIP 2Health News:15% of Women Struggle With Pregnancy-Related Depression 2Health News:15% of Women Struggle With Pregnancy-Related Depression 3Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 2Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 3Health News:Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd. 4Health News:ABR-Affinity BioReagents Expands 100% Quality Guarantee 2Health News:Acute lung injury patients one-third less likely to die in 'closed' model ICUs 2Health News:Acute lung injury patients one-third less likely to die in 'closed' model ICUs 3Health News:Meditation therapy for rheumatoid arthritis patients 2Health News:Meditation therapy for rheumatoid arthritis patients 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: